Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Names Several Partners for New TruSeq, Nextera Program

NEW YORK (GenomeWeb News) – Illumina today said that it has launched a partnership program aimed at developing automation methods for its TruSeq and Nextera Sample Preparation kits.

The initial partners in the program include Beckman Coulter Life Sciences, PerkinElmer, Eppendorf, Tecan, and Hamilton Robotics. Under the partnerships, sample prep kits sold by Illumina will be automated by the partners, who will develop, distribute, and install methods on the customers' instruments and provide technical support.

Illumina makes TruSeq Sample Prep and Exome Enrichment Kits for DNA, RNA, and small RNA sequencing applications. Its Nextera XT DNA sample preparation kit is used for preparing and sequencing small genomes, PCR amplicons, and plasmids.

Illumina said that it will assist the partners in developing, testing, and promoting the automated methods. It expects automated methods for the TruSeq RNA Sample Preparation kits to be available by the end of the second quarter of this year with additional methods for other TruSeq and Nextera kits to follow.

Financial and other terms of the partnerships were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.